Archive | Pharmaceuticals RSS feed for this archive
TechWireBoxYellow

Corner Office – Greg Mario the CEO of TAXISPharma

After more than two decades as a manager and marketer for Big Pharma, Greg Mario co-founded Mario Family Partners, a biotech venture capital firm, in 2001. He earned hisMBA at Duke and his undergraduate degree in biochemistry at Trinity College in Connecticut. He lives with his family in Princeton. Continue Reading

Continue Reading

Pfizer And Astrazeneca Enter Into Agreement For Over-The-Counter Nexium

NEXIUM 20mg Retail Launch in the U.S. Targeted for 2014, Subject to Regulatory Approval Pfizer Updates Certain Elements of 2012 Financial Guidance to Reflect the Transaction NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that it has entered into an agreement with AstraZeneca for the over-the-counter (OTC) rights for NEXIUM (esomeprazole magnesium), a leading prescription […]

Continue Reading

PDI, Inc. Announces $29 Million in New and Extended Sales Contracts

PARSIPPANY, N.J., July 25, 2012 /PRNewswire/ — PDI, Inc. (Nasdaq: PDII) today announced the signing of several new and extended contracts, including two new wins from Top 10 global pharmaceutical companies. Together the contracts are expected to generate total revenues of $29 million over the lives of the contracts. $12 – $13 million of revenue […]

Continue Reading

The Medicines Company Expects Cangrelor Phase 3 Trial Enrollment Completion in 2012

Review Committee Recommends Sample Size of 10,900 Patients Based on Interim Analysis PARSIPPANY, NJ, Jul 02, 2012 (MARKETWIRE via COMTEX) –The Medicines Company (NASDAQ: MDCO) today announced it expects to complete patient enrollment of the pivotal Phase 3 CHAMPION PHOENIX trial of cangrelor in fourth quarter of 2012. The Company accepted the recommendation of a […]

Continue Reading

AstraZeneca and The Medicines Company Announce Global Collaboration in Acute Ischemic Heart Disease

Global Development and Commercialization Agreement to Begin with Co-Promotion of BRILINTA (ticagrelor) in United States WILMINGTON, Del. & PARSIPPANY, N.J., Apr 25, 2012 (BUSINESS WIRE) –AstraZeneca (NYSE: AZN) and The Medicines Company (NASDAQ: MDCO) announced today a global collaboration for acute ischemic heart disease compounds. Read More

Continue Reading

Ceptaris Secures $15M in Venture Debt Financing

MALVERN, PA (February 21, 2012) – Ceptaris Therapeutics, Inc., a privately held specialty pharmaceutical company, today secured $15 million in venture debt financing from Silicon Valley Bank and Oxford Finance. The New Drug Application (NDA) for Ceptaris’ drug candidate, mechlorethamine gel, is currently undergoing review by the U.S. Food and Drug Administration (FDA) for the […]

Continue Reading

IntegriChain Delivers Pharmacy Level Inventory Metrics

PRINCETON, N.J., Feb. 15, 2012 /PRNewswire via COMTEX/ — IntegriChain Inc., a commercial provider of data and analytic insights to the pharmaceutical industry, announced today the introduction of a new methodology for its DNA: Inventory – Retail solution that adds the ability to report on independent and chain pharmacies’ inventory levels, by product NDC code, […]

Continue Reading

PDI, Inc. Announces $48 Million in Renewal Sales Contracts

PARSIPPANY, N.J., Feb. 14, 2012 /PRNewswire/ — PDI, Inc. (Nasdaq: PDII) today announced the signing of a three-year agreement with a current Top 5 global pharmaceutical client and renewal of a one-year engagement with a specialty pharmaceutical client. Approximately $48 million in revenue is expected to be generated in 2012 between both contracts. Read more […]

Continue Reading

New Jersey – Tax Cuts, Regulatory Reform and Business Advocacy Redefine New Jersey in the Marketplace

By: Lt. Governor Kim Guadagno Since taking office in January 2010, Governor Chris Christie has chosen a new direction for New Jersey – lowering taxes, reducing bureaucracy that stifles economic development, and restructuring government so that the Garden State is a place where business growth is fostered and encouraged. Read more of this entry

Continue Reading

New Select Study Finds: Greater Philadelphia is a Major U.S. Center for R&D

A new study by Select Greater Philadelphia finds that the region is a top U.S. center for research and development (R&D) activity, a key to economic growth. Select found that Greater Philadelphia is among the nation’s top five R&D hubs… from Momentum!

Continue Reading
Follow

Get every new post delivered to your Inbox.

Join 85 other followers